KM-023

DRUG2 trials

Sponsors

Kainos Medicine Inc., Orvida Pharma (formerly Kamari Pharma)

Conditions

Human Immunodeficiency VirusOlmsted Syndrome

Phase 1

Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023

CompletedNCT01348516

Kainos Medicine Inc.Human Immunodeficiency Virus

Start: 2011-05-31Updated: 2012-07-26

Study of KM-023 in Healthy Volunteers and Patients With Olmsted Syndrome.

RecruitingNCT07090889

Orvida Pharma (formerly Kamari Pharma)Olmsted Syndrome

Start: 2025-07-08End: 2026-11-21Target: 64Updated: 2026-05-22